ArticleSignal transduction and targeted therapy2023

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer.

Yiqun Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.